Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tempest Therapeutics ( (TPST) ) has shared an announcement.
Tempest Therapeutics, Inc. has entered into an Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc., involving the acquisition of assets related to CAR T-cell therapies. The transaction, expected to close in early 2026, will result in significant changes in the company’s leadership, with Dr. Matt Angel appointed as CEO and President. The deal includes the issuance of shares and warrants, and is subject to stockholder approval and other conditions.
The most recent analyst rating on (TPST) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Underperform.
Tempest Therapeutics scores low primarily due to its financial performance, marked by a lack of revenues and high expenditures, leading to ongoing losses. The technical analysis indicates a bearish trend, further impacting the score. Valuation metrics are challenging to apply due to the negative earnings, typical for its growth stage. Overall, the stock presents high risk with potential for high reward contingent on future developments.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Average Trading Volume: 46,434
Technical Sentiment Signal: Sell
Current Market Cap: $41.65M
For a thorough assessment of TPST stock, go to TipRanks’ Stock Analysis page.